Talphera (TLPH) Retained Earnings (2010 - 2026)
Talphera (TLPH) posted Retained Earnings of $492.7 million for Q2 2026, little changed on a QoQ basis from $492.5 million in Q1 2026, and up 4.86% year-over-year from $469.9 million in Q2 2025.
Analysis
Talphera (TLPH) Retained Earnings (2010 - 2026) Analysis & Trends
Talphera has reported Retained Earnings for 17 years, with the latest figure at $492.7 million in Q2 2026.
- On a quarterly basis, Retained Earnings rose 4.86% year-over-year to $492.7 million in Q2 2026; TTM through Jun 2026 was $492.7 million, a 4.86% increase from a year earlier, with the FY2025 full-year figure at $488.5 million, up 5.01% from the prior year.
- Retained Earnings was $492.7 million for Q2 2026 at Talphera, roughly flat from $492.5 million in the prior quarter.
- The five-year high for Retained Earnings was $492.7 million in Q2 2026, with the low at -$482.3 million in Q1 2022.
- Average Retained Earnings over 5 years is $412.5 million, with a median of $464.6 million recorded in 2024.
- The largest YoY upside for Retained Earnings was 197.22% in 2022 against a maximum downside of 7.78% in 2022.
- Over 5 years, Retained Earnings stood at $447.6 million in 2022, then rose by 2.39% to $458.3 million in 2023, then advanced by 1.51% to $465.2 million in 2024, then rose by 5.01% to $488.5 million in 2025, then gained by 0.87% to $492.7 million in 2026.
- The last three Retained Earnings figures came in at $492.7 million (Q2 2026), $492.5 million (Q1 2026), and $488.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 5.13 Bn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | 492.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 492.74 Mn |
| Mar 31, 2026 | 492.50 Mn |
| Dec 31, 2025 | 488.51 Mn |
| Sep 30, 2025 | 486.88 Mn |
| Jun 30, 2025 | 469.92 Mn |
| Mar 31, 2025 | 465.41 Mn |
| Dec 31, 2024 | 465.21 Mn |
| Sep 30, 2024 | 464.98 Mn |
| Jun 30, 2024 | 464.72 Mn |
| Mar 31, 2024 | 464.50 Mn |
| Dec 31, 2023 | 458.31 Mn |
| Sep 30, 2023 | 458.00 Mn |
| Jun 30, 2023 | 448.76 Mn |
| Mar 31, 2023 | 448.21 Mn |
| Dec 31, 2022 | 447.64 Mn |
| Sep 30, 2022 | 445.56 Mn |
| Jun 30, 2022 | 444.59 Mn |
| Mar 31, 2022 | -482.26 Mn |
| Dec 31, 2021 | -473.58 Mn |
| Sep 30, 2021 | -465.67 Mn |